Advertisement
UK markets open in 26 minutes
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,787.00
    +275.31 (+1.67%)
     
  • CRUDE OIL

    83.02
    +0.17 (+0.21%)
     
  • GOLD FUTURES

    2,315.90
    -30.50 (-1.30%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • Bitcoin GBP

    53,920.05
    +146.33 (+0.27%)
     
  • CMC Crypto 200

    1,402.12
    -12.64 (-0.89%)
     
  • NASDAQ Composite

    15,451.31
    +169.30 (+1.11%)
     
  • UK FTSE All Share

    4,362.60
    +66.19 (+1.54%)
     

How Novartis’s Sandoz Has Performed

How Novartis’s Sandoz Has Performed

Novartis’s (NVS) Sandoz, a market leader in differentiated generics, saw its revenue grow 4% YoY (year-over-year) to ~$2.5 billion in Q1 2018, boosted by 8% due to foreign exchange and offset by a 4% decline in operating revenue. The chart below shows Sandoz’s quarterly revenue since Q1 2017.